JPWO2020120449A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020120449A5
JPWO2020120449A5 JP2021533341A JP2021533341A JPWO2020120449A5 JP WO2020120449 A5 JPWO2020120449 A5 JP WO2020120449A5 JP 2021533341 A JP2021533341 A JP 2021533341A JP 2021533341 A JP2021533341 A JP 2021533341A JP WO2020120449 A5 JPWO2020120449 A5 JP WO2020120449A5
Authority
JP
Japan
Prior art keywords
disorder
disorders
disease
pharmaceutical composition
following group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533341A
Other languages
English (en)
Japanese (ja)
Other versions
JP7408662B2 (ja
JP2022512374A5 (https=
JP2022512374A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/084373 external-priority patent/WO2020120449A1/en
Publication of JP2022512374A publication Critical patent/JP2022512374A/ja
Publication of JPWO2020120449A5 publication Critical patent/JPWO2020120449A5/ja
Publication of JP2022512374A5 publication Critical patent/JP2022512374A5/ja
Application granted granted Critical
Publication of JP7408662B2 publication Critical patent/JP7408662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533341A 2018-12-12 2019-12-10 置換キサンタン誘導体 Active JP7408662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18212059 2018-12-12
EP18212059.2 2018-12-12
PCT/EP2019/084373 WO2020120449A1 (en) 2018-12-12 2019-12-10 Substituted xanthine derivatives

Publications (4)

Publication Number Publication Date
JP2022512374A JP2022512374A (ja) 2022-02-03
JPWO2020120449A5 true JPWO2020120449A5 (https=) 2022-12-16
JP2022512374A5 JP2022512374A5 (https=) 2022-12-16
JP7408662B2 JP7408662B2 (ja) 2024-01-05

Family

ID=64665183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533341A Active JP7408662B2 (ja) 2018-12-12 2019-12-10 置換キサンタン誘導体

Country Status (5)

Country Link
US (1) US12291532B2 (https=)
EP (1) EP3894409B1 (https=)
JP (1) JP7408662B2 (https=)
CN (1) CN113166150B (https=)
WO (1) WO2020120449A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3894409B1 (en) * 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives
KR20250141831A (ko) * 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도
WO2024236027A1 (en) * 2023-05-18 2024-11-21 Boehringer Ingelheim International Gmbh 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione for use in the treatment of borderline personality disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899646C (en) 2013-03-15 2021-08-31 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
JP6667093B2 (ja) 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピリド[2,3−d]ピリミジン−2,4(1H,3H)−ジオン誘導体
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
SI3652176T1 (sl) * 2017-07-11 2022-04-29 Boehringer Ingelheim International Gmbh Substituirani ksantinski derivati
EP3894409B1 (en) * 2018-12-12 2023-08-23 Boehringer Ingelheim International GmbH Substituted xanthine derivatives

Similar Documents

Publication Publication Date Title
RU2015143466A (ru) Нейроактивные стероиды и способы их применения
JP2016513663A5 (https=)
JP2004534816A5 (https=)
JP2020526591A5 (https=)
JP2018070614A5 (https=)
MXPA05012391A (es) Tratamiento de trastornos psicoticos y depresivos.
JP2018508592A5 (https=)
JP2005527593A5 (https=)
JP2017531020A5 (https=)
JP2019525939A5 (https=)
RU2002107203A (ru) Производные N-гетероциклических соединений в качестве ингибиторов синтазы оксида азота (nos)
JP2021531291A5 (https=)
JP2007508358A5 (https=)
JP2020502047A5 (https=)
JP2007508360A5 (https=)
JP2015523406A5 (https=)
JP2020504156A5 (https=)
HRP20221240T1 (hr) Deuterirani analozi etifoksina, njihovi derivati i njihove uporabe
HRP20220029T1 (hr) Supstituirani derivati ksantina
JP2019516739A5 (https=)
JP2022065035A5 (https=)
JP2019513745A5 (https=)
JP2020520911A5 (https=)
JPWO2020120449A5 (https=)
EA201990450A1 (ru) Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания